



••• Hallett H. Mathews, M.D.  
Spine Surgery  
••• Bruce E. Mathern, M.D.  
Neurological Surgery

••• Paul P. DiMartino, M.D.  
Spine Surgery  
• Michael J. Decker, M.D.  
Pain Medicine

• Jeffrey D. Moore, M.D.  
Spine & Orthopaedic Surgery  
• Paul E. Savas, M.D.  
Spine & Orthopaedic Surgery

4791 '00 NOV 15 P2:21

November 6, 2000

Dockets Management Branch (HFA 305)  
U.S. Food and Drug Administration  
5630 Fishers Lane, Rm 1061  
Rockville, MD 20852

Dear Sir or Madam:

I am writing in strong opposition to the FDA's intention to reclassify Totally Implantable Spinal Cord Stimulators (SCS) from Class III to Class II. Such a move would eliminate some critical checks and balances that help promote patient safety.

SCS devices are extremely complex. They involve highly intricate and specialized circuitry and a power source that is totally implantable with leads surgically placed into the spinal area. The devices themselves are as complex as the procedure to implant them.

I am deeply concerned that the potential reclassification of this device to Class II opens the door to allow a lower standard of product in the market that could potentially endanger the lives of patients. As a physician who treats chronic pain patients on a regular basis, I am concerned for their safety as well as the integrity of my practice.

Even with implantable SCS devices already approved by FDA, not all safety features are well understood. To ensure patient safety, it is critical to have manufacturing checks for any potential manufacturer of these devices.

I am compelled to note that in 1995, FDA itself deemed these devices "potentially high risk". The fact that the agency is planning to downgrade them now is cause for great concern.

I firmly believe that reclassification of these devices compromises the integrity of the entire class, a misstep that undoubtedly will jeopardize future patients (many of whom have lived with serious pain for years) from potentially receiving the only therapy that could help them. The FDA classification level III with the corresponding Pre-Market Approval is imperative to protecting the safety of patients receiving these complex technologically-advanced devices.

Thank you for your careful consideration of my comments. Please contact my office if I can provide you with additional information.

Sincerely,

Michael J. Decker, M.D.

MJD/few

00P-0788

C29

CROSS FILE SHEET

File Number: 00D-1455/C27

See File Number: 00P-0788/C29